Processing

Please wait...

Settings

Settings

Goto Application

1. RU0002676475 - NEW FUNCTIONALIZED 1,3-BENZENEDIOLS AND METHOD FOR APPLICATION THEREOF FOR TREATMENT OF HEPATIC ENCEPHALOPATHY

Office
Russian Federation
Application Number 2016133213
Application Date 09.01.2015
Publication Number 0002676475
Publication Date 29.12.2018
Grant Number
Grant Date 29.12.2018
Publication Kind C2
IPC
C07D 249/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
249Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
A61K 31/397
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
397having four-membered rings, e.g. azetidine
A61K 31/4192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41921,2,3-Triazoles
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 205/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
205Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
02not condensed with other rings
04having no double bonds between ring members or between ring members and non-ring members
CPC
A61K 31/397
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
397having four-membered rings, e.g. azetidine
A61K 31/4192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41921,2,3-Triazoles
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 21/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
02Muscle relaxants, e.g. for tetanus or cramps
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
Inventors БРЕННЕМАН Дуглас Е. (US)
КИННИ Уильям Элвин (US)
МАКДОННЕЛЛ Марк (US)
ПЕТКАНАС Дин (US)
BRENNEMAN Duglas E. (US)
KINNI Uilyam Elvin (US)
MAKDONNELL Mark (US)
PETKANAS Din (US)
Priority Data 61/926,869 13.01.2014 US
Title
(EN) NEW FUNCTIONALIZED 1,3-BENZENEDIOLS AND METHOD FOR APPLICATION THEREOF FOR TREATMENT OF HEPATIC ENCEPHALOPATHY
(RU) Новые функционализированные 1,3-бензолдиолы и способ их применения для лечения печеночной энцефалопатии
Abstract
(EN) FIELD: chemistry. SUBSTANCE: invention relates to a compound having the formula (I) and its pharmaceutically acceptable salts. In formula (I), A is where R1 is selected from the group consisting of W represents (CH2)m; m is 1; Y is (CH2)q; q is 1; n is 1 or 2; R3 is a COR5 or CO2R6; each of R4a, R4b and R4c is hydrogen; R5 represents C1-6alkyl; and R6 represents C1-6alkyl. Invention also relates to a pharmaceutical composition, to a method for treating or preventing a disease, the etiology of which is associated with stress mediated by free radicals, or oxidative stress, or treating or preventing a condition associated with the disease. EFFECT: technical result: obtained new compounds of formula (I) are able to act as neuroprotective agents. 8 cl, 2 dwg, 9 tbl, 3 ex
(RU) Изобретение относится к соединению, имеющему формулу (I) и его фармацевтически приемлемым солям. В формуле (I) А представляет собой где R1 выбран из группы, состоящей из W представляет собой (СН2)m; m равен 1; Y представляет собой (CH2)q; q равен 1; n равен 1 или 2; R3 представляет собой COR5 или CO2R6; каждый из R4a, R4b и R4c представляет собой водород; R5 представляет собой C1-6алкил; и R6 представляет собой С1-6алкил. Изобретение также относится к фармацевтической композиции, к способу лечения или предотвращения заболевания, этиология которого связана со стрессом, опосредованным свободными радикалами, или окислительным стрессом, или лечения или предотвращения состояния, связанного с указанным заболеванием. Технический результат: получены новые соединения формулы (I), которые способны действовать в качестве нейропротекторных агентов. 3 н. и 5 з.п. ф-лы, 2 ил., 9 табл., 3 пр.
Related patent documents
BR112016016138This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.